AU2001282118A1 - Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases - Google Patents

Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Info

Publication number
AU2001282118A1
AU2001282118A1 AU2001282118A AU8211801A AU2001282118A1 AU 2001282118 A1 AU2001282118 A1 AU 2001282118A1 AU 2001282118 A AU2001282118 A AU 2001282118A AU 8211801 A AU8211801 A AU 8211801A AU 2001282118 A1 AU2001282118 A1 AU 2001282118A1
Authority
AU
Australia
Prior art keywords
airway diseases
positively influence
identifying substances
chronic inflammatory
inflammatory conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282118A
Inventor
Birgit Jung
Barbara Kistler
Norbert Kraut
Stefan Muller
Karsten Quast
Peter Seither
Andreas Weith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Publication of AU2001282118A1 publication Critical patent/AU2001282118A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AU2001282118A 2000-09-01 2001-08-23 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases Abandoned AU2001282118A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0021484.1A GB0021484D0 (en) 2000-09-01 2000-09-01 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
GB0021484 2000-09-01
PCT/EP2001/009727 WO2002018938A1 (en) 2000-09-01 2001-08-23 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Publications (1)

Publication Number Publication Date
AU2001282118A1 true AU2001282118A1 (en) 2002-03-13

Family

ID=9898663

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282118A Abandoned AU2001282118A1 (en) 2000-09-01 2001-08-23 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Country Status (7)

Country Link
EP (1) EP1315963A1 (en)
JP (1) JP2004507262A (en)
AU (1) AU2001282118A1 (en)
CA (1) CA2418506C (en)
GB (1) GB0021484D0 (en)
MX (1) MXPA03001506A (en)
WO (1) WO2002018938A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364017A2 (en) * 2000-08-18 2003-11-26 Novartis AG Inflammation related g-protein coupled receptor
AU2002332929A1 (en) 2001-09-07 2003-03-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US20050164305A1 (en) * 2002-04-03 2005-07-28 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
EP1597586A2 (en) * 2003-02-13 2005-11-23 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with hm74
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
AU2005216878B2 (en) * 2004-02-20 2010-06-17 Aventis Pharmaceuticals Inc. Oxydecahydronaphthalene modulators of HM74
AU2005216879B2 (en) * 2004-02-20 2009-12-10 Aventis Pharmaceuticals Inc Furosemide derivatives as modulators of HM74 and their use for the treatment of inflammation
WO2007067912A2 (en) * 2005-12-07 2007-06-14 Boehringer Ingelheim International Gmbh Treatment and diagnostics of inflammatory diseases
JP6151129B2 (en) * 2013-08-19 2017-06-21 テルモ株式会社 Fibrotic agent
JP6210794B2 (en) * 2013-08-19 2017-10-11 テルモ株式会社 Fibrotic agent
PL3658589T3 (en) 2017-07-26 2024-03-18 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648344A (en) * 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
AU8337291A (en) * 1990-08-06 1992-03-02 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
WO1994025570A1 (en) * 1993-04-23 1994-11-10 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents
US6160088A (en) * 1998-07-29 2000-12-12 Sloan-Kettering Institute For Cancer KDEL receptor inhibitors
WO2000031261A2 (en) * 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor
CA2354673A1 (en) * 1998-12-11 2000-06-15 Children's Hospital Medical Center Method for determining asthma susceptibility
EP1364017A2 (en) * 2000-08-18 2003-11-26 Novartis AG Inflammation related g-protein coupled receptor

Also Published As

Publication number Publication date
JP2004507262A (en) 2004-03-11
CA2418506A1 (en) 2002-03-07
EP1315963A1 (en) 2003-06-04
WO2002018938A1 (en) 2002-03-07
CA2418506C (en) 2009-04-28
GB0021484D0 (en) 2000-10-18
MXPA03001506A (en) 2003-06-09

Similar Documents

Publication Publication Date Title
AU2003250829A1 (en) System and method for the automatic detection of the expiratory flow limitation
AU2002316137A1 (en) Method of determining protein interaction inhibitors
AU7861800A (en) Method for determining total cost of ownership
AU2001282118A1 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
AU2002312859A1 (en) Method for determining gene expression
AU2002216080A1 (en) Method for determining competing risks
AU2000256675A1 (en) Inspection system for edges of glass
AU2001257903A1 (en) Method for treatment of neurodegenerative diseases
AU2002326949A1 (en) Method for the inhibition of methanogenesis
AU2001271841A1 (en) Methods for identifying combinations of drugs
AU2003220034A1 (en) An early detection marker for chronic inflammatory associated diseases
AU2002238274A1 (en) Method for the detection of nucleic acid molecules
AU2001287268A1 (en) Method of identifying inhibitors of tie-2
AU2002301109A1 (en) Method for the prediction of preeclampsia and other diseases
AU2002221950A1 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
AU2002240840A1 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
WO2002052270A3 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
AU2001227708A1 (en) Methods for identifying inhibitors of neuronal degeneration
AU2003223041A1 (en) Method for analysis of methylated nucleic acids
AU6346901A (en) Method of detecting inflammatory lung disorders
AU2001265050A1 (en) Practical screening method for detecting genetic disorders of sterol metabolism
WO2002052269A3 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
GB0029539D0 (en) Method for identifying modulatorss of transcription
AU2001260463A1 (en) Method for analysis of metabolic pathways
AU2001253092A1 (en) Method for detection of truncated proteins